Search Results - "Stuart WH"

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.

Authors: Lefort, M. Sharmin, S. Andersen, J. B. et al.

Source: BMC Medical Research Methodology. 5/30/2022, Vol. 22 Issue 1, p1-14. 14p.

Rethinking MS Therapeutics: From Disease Pathogenesis Mechanisms to AI-Driven Drug Discovery.

Authors: Ziaei M Sehhati M Torabi M et al.

Source: Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology [J Neuroimmune Pharmacol] 2026 Apr 13; Vol. 21 (1). Date of Electronic Publication: 2026 Apr 13.

Publication Type: Journal Article; Review

Journal Info: Publisher: Springer Science + Business Media Country of Publication: United States NLM ID: 101256586 Publication Model: Electronic Cited Medium: Internet ISSN: 1557-1904 (Electronic) Linking ISSN: 15571890 NLM ISO Abbreviation: J Neuroimmune Pharmacol Subsets: MEDLINE

Cost-Consequences of Cladribine Tablets for the Treatment of Highly Active Relapsing–Remitting Multiple Sclerosis in Italy.

Authors: Polistena, Barbara Provenzano, Anna Maria Rizzi, Caterina et al.

Source: Neurology & Therapy. Aug2025, Vol. 14 Issue 4, p1507-1520. 14p.

Natalizumab for multiple sclerosis.

Authors: Liu C Cai Z Zhao L et al.

Source: The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2025 Aug 06; Vol. 8. Cochrane AN: CD015123. Date of Electronic Publication: 2025 Aug 06.

Publication Type: Journal Article; Systematic Review; Meta-Analysis

Journal Info: Publisher: Wiley Country of Publication: England NLM ID: 100909747 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-493X (Electronic) Linking ISSN: 13616137 NLM ISO Abbreviation: Cochrane Database Syst Rev Subsets: MEDLINE

Qualified placebo for trials of herbal medicine treatment in rare diseases? A cross-sectional analysis.

Authors: Li, Yixuan Du, Peipei Zhang, Xuebin et al.

Source: Orphanet Journal of Rare Diseases. 11/30/2023, Vol. 18 Issue 1, p1-12. 12p.

The Present and Future of Monoclonal Antibody Therapies for Multiple Sclerosis.

Authors: Susin-Calle S Munteis E Villoslada P et al.

Source: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2025 Nov; Vol. 39 (6), pp. 815-826. Date of Electronic Publication: 2025 Sep 23.

Publication Type: Journal Article; Review

Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9705305 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-190X (Electronic) Linking ISSN: 11738804 NLM ISO Abbreviation: BioDrugs Subsets: MEDLINE

Treatment Options for the Comorbidity of Multiple Sclerosis with Other Chronic Inflammatory Diseases.

Authors: Bittner, S. Kriegel, M. A. Siegmund, B. et al.

Source: Deutsches Ärzteblatt International. 8/8/2025, Vol. 122 Issue 16, p8-8. 1p.

Paradoxical Tumefactive Worsening of Multiple Sclerosis After Natalizumab Initiation: A Case Report.

Authors: Ahern, Cathal¹ cathalahern@gmail.com

Source: touchREVIEWS in Neurology. 2023, Vol. 19 Issue 2, p19-22. 4p.

Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing–Remitting Multiple Sclerosis: STRIVE Data Analysis.

Authors: Perumal, Jai Balabanov, Roumen Balcer, Laura et al.

Source: Neurology & Therapy. Jun2023, Vol. 12 Issue 3, p833-848. 16p.

Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM.

Authors: Williams, Mitzi J. Amezcua, Lilyana Okai, Annette et al.

Source: Neurology & Therapy. Dec2020, Vol. 9 Issue 2, p483-493. 11p.

Vaccine-associated measles in a patient treated with natalizumab: a case report.

Authors: Miauton, Alix Tan, Rainer Pantazou, Vasiliki et al.

Source: BMC Infectious Diseases. 10/14/2020, Vol. 20 Issue 1, p1-4. 4p.

The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study.

Authors: Mazdeh, Mehrdokht Hosseini, Shno Taheri, Mohammad et al.

Source: Clinical & Translational Medicine. Dec2018, Vol. 7 Issue 1, p1-5. 5p.

Disease‐modifying therapies and T1 hypointense lesions in patients with multiple sclerosis: A systematic review and meta‐analysis.

Authors: Valizadeh, Amir Fattahi, Mohammad Reza Sadeghi, Maryam et al.

Source: CNS Neuroscience & Therapeutics. May2022, Vol. 28 Issue 5, p648-657. 10p.

The evolution of multiple sclerosis disease-modifying therapies: An update for pharmacists.

Authors: Edinger, Alexandra Habibi, Mitra

Source: American Journal of Health-System Pharmacy. Jan2024, Vol. 81 Issue 2, p37-55. 19p.

Targeting T-cell integrins in autoimmune and inflammatory diseases.

Authors: Kelly, Aidan J Long, Aideen

Source: Clinical & Experimental Immunology. Jan2024, Vol. 215 Issue 1, p15-26. 12p.

Disease‐modifying therapies in multiple sclerosis: A focused review of rituximab.

Authors: Alping, Peter¹ (AUTHOR) peter.alping@ki.se

Source: Basic & Clinical Pharmacology & Toxicology. Nov2023, Vol. 133 Issue 5, p550-564. 15p.

The Prevalence of Cancer in Patients with Multiple Sclerosis (MS) who were Under Treatment with Natalizumab (Tysabri): A Systematic Review and Meta-Analysis.

Authors: Nasirzadeh, Amirreza Jahanshahi, Reza Ghajarzadeh, Mahsa et al.

Source: International Journal of Preventive Medicine. Sep2023, Vol. 14 Issue 1, p1-5. 5p.

Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study).

Authors: Okai, Annette F. Amezcua, Lilyana Berkovich, Regina R. et al.

Source: Neurology & Therapy. Dec2019, Vol. 8 Issue 2, p367-381. 15p.

The effect of atomoxetine on cognitive function in patients with multiple sclerosis.

Authors: Nejad, Ehsan Mohammadian Amouzadeh, Effat Kashipazha, Davood et al.

Source: Current Journal of Neurology. 2023, Vol. 22 Issue 3, p149-154. 6p.

High levels of endothelial ICAM-1 prohibit natalizumab mediated abrogation of CD4⁺ T cell arrest on the inflamed BBB under flow in vitro.

Authors: Soldati, Sasha Bär, Alexander Vladymyrov, Mykhailo et al.

Source: Journal of Neuroinflammation. 5/23/2023, Vol. 20 Issue 1, p1-22. 22p.